Coronary artery disease (CAD)-related events such as acute coronary syndrome, revascularization procedures, and cardiovascular death remain significant sources of morbidity, mortality, and cost. 1 In patients presenting with symptoms suggestive of CAD, an initial goal of diagnostic testing is to determine the presence and extent of CAD and to identify whether obstructive CAD (oCAD) may be the etiology of the patient's symptoms. 2 An equally important goal of noninvasive testing is cardiovascular prognosis. [2] [3] [4] Early identification of a patient's risk for CAD-related events or procedures can help patients and providers decide whether to pursue invasive diagnostic testing and intensify cardiovascular risk factor modification in high-risk patients or look elsewhere for symptom causality in low-risk patients. 2, 5, 6 The application of molecular profiling has transformed our ability to identify potential, novel risk biomarkers. Specifically, measurements of the "expressed genome"-RNA, proteins, and metabolites-can provide a molecular snapshot of the patient to potentially provide a more granular estimate of cardiovascular risk. Two concepts motivated the development of an age-and sex-specific gene expression score (ASGES) for oCAD: (1) that circulating blood cells may be reporting on the degree of atherosclerosis in the coronary tree due to changes in their composition and function due to underlying inflammatory pathways and (2) that the RNA content of blood cells is, in part, a reflection of their function and cell-type. In prior studies, we developed an ASGES that is associated with the likelihood of oCAD as defined by quantitative coronary angiography (QCA) with high sensitivity and high negative predictive value, and without exposure to radiation or contrast agents, in a population referred for invasive angiography. [7] [8] [9] The ASGES is reported on a 1-40 scale, with lower scores associated with lower likelihood of oCAD. 8 We subsequently independently validated the ASGES in a lower-risk population of symptomatic, nondiabetic patients referred for myocardial perfusion imaging using a composite hierarchical anatomic endpoint of QCA and core laboratory-read coronary computed tomographic angiography (CTA) to define oCAD. 10 In that population, use of a prospectively defined ASGES threshold of 15 showed a sensitivity of 89% and negative predictive value of 96%. Based on these prior studies, the ASGES is a clinically available diagnostic tool (Corus® CAD) for evaluating patients with symptoms suggestive of oCAD. In exploratory analyses performed in our earlier studies, patients with an ASGES ≤15 had a lower likelihood of a CAD-related event-defined as death, myocardial infarction (MI), stroke, or revascularization procedure-6-12 months after testing. 10, 11 However, these analyses were limited by length of follow-up and very low numbers of events.
The Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) randomized controlled trial compared diagnostic testing strategies in outpatients presenting with symptoms suggestive of oCAD. 12 The primary objective of this PROMISE trial substudy was to use baseline blood samples from nondiabetic trial participants to test the hypothesis that the ASGES was associated with CAD-related events in nondiabetic patients, and that patients with a low ASGES had a low likelihood of subsequent events. We also aimed to validate the association between ASGES and CAD burden in the PROMISE CTA data.
Methods

PROMISE trial design and patient population
The PROMISE trial recruited symptomatic outpatients at increased risk for CAD based on age and/or the presence of CAD risk factors. 13 The mean (±SD) age of PROMISE trial participants was 61 (±8) years; 53% were women, 23% non-white, 25% with a CAD risk equivalent, and 32% with a family history of CAD. 12 Major PROMISE exclusion criteria included recent acute coronary syndrome, known CAD, or history of MI. The PROMISE trial randomized 10,003 patients to either functional (ie, exercise, echocardiographic, or nuclear stress testing) or anatomic (ie, CTA) diagnostic testing and tested the hypothesis that anatomic testing would improve clinical outcomes (death, MI, unstable angina hospitalization [UA], revascularization, and peri-procedural complications). In the trial, anatomic testing did not improve clinical outcomes compared to functional testing. 12 PROMISE trial biorepository and sample selection PROMISE participants were approached to consent for baseline biological specimen collection including whole blood in PAXgene tubes (Pre-Analytix, Valencia, CA) for RNA analyses. (See online Supplementary Methods for full details.)
RNA purification, qPCR, and ASGES determination RNA was purified and analyzed for quality and quantity, and the ASGES was determined by RT-qPCR in an automated fashion as previously described. 7, 14, 15 (See online Supplementary Methods for full details.) All samples were processed according to Corus CAD protocols in the CardioDx CLIA laboratory (CLIA License # 05D1083624). The ASGES ranges from 1-40 and is rounded to the nearest integer.
Study endpoints and definitions
The primary clinical endpoint for this analysis was a composite of death from any cause, MI, UA, or revascularization. This endpoint, while different from that of the parent trial in that major procedural complications were excluded and revascularization was included, was chosen to replicate that used in previous ASGES studies to better enable comparisons across studies and populations. Secondary clinical endpoints included each component of the primary clinical endpoint as well as the composite of death from any cause, MI, and UA. Obstructive CAD was defined as ≥70% stenosis in a major coronary artery or ≥50% left main stenosis using CTA data. A negative noninvasive test was defined as a negative or low-risk test result, and a positive test was defined as a moderately or severely abnormal test result. See online Supplementary Obstructive coronary artery disease. A logistic regression model was used to assess the relationship between ASGES and oCAD using a predetermined threshold value of 15 that was validated in prior studies. 10 An odds ratio (OR) and 95% confidence interval (CI) are reported to characterize the likelihood of oCAD for subjects with ASGES N15 compared to subjects with ASGES ≤15. The discriminatory ability and the calibration of the ASGES model with respect to oCAD were assessed by calculating the area under a receiver operating characteristic (AUC) curve and the Hosmer-Lemeshow goodness-of-fit test, 16 respectively. An ordinal logistic regression model was used to assess the relationship between continuous ASGES and the extent of CAD (defined by maximum stenosis: no CAD, 1-49% stenosis in a single vessel, ≥50% stenosis in a single vessel, ≥50% stenosis in 2 or more vessels). The proportional odds assumption was verified, and an OR and 95% CI were reported to characterize the change in likelihood of having greater extent of CAD based on a one-unit increase in continuous ASGES.
Prognostic analyses. The Cox proportional hazards regression model was used to assess the relationship between ASGES and time to first clinical event (or censoring) for primary and secondary endpoints. To account for baseline characteristics associated with ASGES, analyses were adjusted using the Framingham risk score (FRS) or CTA-defined oCAD. Unadjusted and adjusted hazard ratios and CIs are reported to characterize the difference in risk between subjects with ASGES ≤15 and those with ASGES N15. Cumulative event rates based on ASGES group (≤15, N15) were computed using the Kaplan-Meier method. 17 Similar analyses were performed for continuous ASGES (range, 1-40). In these analyses, continuous ASGES was assumed to have a linear relationship with the log hazard ratio. In addition, the c-index was used to assess the incremental value of adding ASGES to noninvasive test results in discriminating between subjects who experienced the primary composite event from those who did not. 18 The c-indices were calculated for 2 Cox models based on the predicted risk of event within 4 years: (1) noninvasive test results alone vs. (2) ASGES and the noninvasive test results. The difference in model c-indices and its 95% bootstrap CI are reported. Additionally, these Cox models were used to calculate the continuous net reclassification index (NRI) that assessed whether the addition of ASGES to the baseline model that only included noninvasive test results appropriately reclassified subjects according to their risk of experiencing the primary composite event within 4 years. 19 The continuous NRI and its 95% bootstrap CI are reported. The rate of the primary clinical event was also compared between subjects who had an ASGES ≤15 and those who had negative noninvasive tests (functional and CTA) using the method of Thomson to account for overlapping groups. 20 The event rate for each low-risk group and its 95% confidence interval are reported.
For all analyses, P b .05 was considered significant. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
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Results
Of the 3742 PROMISE patients with samples in the biorepository, 809 were excluded due to diabetes and 582 met other exclusionary criteria (mainly poor sample quality and use of anti-inflammatory medications; see online Supplementary Figure 1 and Supplementary Table  II ; patients may have been excluded for more than one criteria). The remaining 2370 patients represented 95% of all nondiabetic PROMISE trial patients with an RNA sample that passed quality control (n = 2494; see Supplementary Figure 1 ) and were representative of the overall non-diabetic PROMISE cohort (Supplementary  Table III) . In this cohort, 45% of patients had an ASGES ≤15. Baseline characteristics associated with a higher vs. lower ASGES included older age, male sex, white race, and higher FRS (Table I) .
To confirm that the ASGES was associated with oCAD, we utilized the subset of PROMISE biorepository patients Association of ASGES and Extent of CAD. Categories of extent of coronary artery disease (CAD, x-axis) were based on coronary computed tomographic angiography data. Odds ratio reflects association between the continuous age-and sex-specific gene expression score (ASGES) and risk of higher extent of CAD category.
with site-read CTA data (n = 1137 Figure 2 ). With respect to secondary endpoints, an ASGES N15 was significantly associated with an increased risk of death/MI/UA and revascularization procedures (Table II) . After adjustment for baseline characteristics using the FRS, 21 the association between an ASGES N15 and the primary endpoint (HR 1.70 [95% CI 1.10-2.64], P = .017) persisted. Analysis of individual endpoint components demonstrated that the only component with which an ASGES N15 was independently associated was revascularization (HR 2.69 [95% CI 1.52-4.79], P b .001), of which the majority (97 of 98) occurred within 90 days of randomization and 78 were percutaneous coronary interventions. Treatment of the ASGES as a continuous variable produced similar results (Table II ). In the subset of patients with site-read CTA data (n = 1137), adjustment for oCAD only partially attenuated the association between an ASGES and revascularization (HR for ASGES N15 = 1.89 [95% CI 0.99-3.60], P =.052, and HR for continuous ASGES =1.03 [95% CI 1.00-1.06], P = .026).
To assess the potential clinical utility of a low (≤15) ASGES to identify low-risk patients, we compared the risk of the primary composite endpoint in 2 patient subgroups: 1) patients with ASGES ≤15 and 2) patients with a negative noninvasive test result (functional test or CTA). Patients with an ASGES ≤15 (n = 1058) had an event rate (3.21%) that was no different (P = .29) from those with negative noninvasive test results (n = 1963, 2.60%). However, the ASGES (≤15, N15) displayed decreased 
Discussion
In stable patients presenting with symptoms suggestive of CAD, clinically relevant questions facing clinicians include the following: Does my patient have CAD? What is the extent of CAD? What is my patient's overall cardiovascular prognosis? Would my patient benefit from further diagnostic testing? Currently, noninvasive diagnostic testing using either functional or anatomic-based approaches can be used to provide information related to these questions. Accurate diagnosis and risk stratification can help guide further invasive diagnostic testing and risk factor modification, and search for alternative, non-cardiac causes of chest pain symptoms in patients with negative test results. In this PROMISE substudy, we used baseline samples to confirm the diagnostic performance and assess the prognostic performance of the ASGES. Validating previous work by our group, 10, 22 we first confirmed that the ASGES was associated with oCAD as assessed by coronary CTA. Next, we showed for the first time that the ASGES was associated with revascularization procedures independent of FRS factors. Third, an ASGES ≤15 (representing 45% of patients) was similar to negative noninvasive test results in identifying a patient subgroup at low risk for the primary endpoint. Last, when added to functional and anatomic test results, the ASGES provided incremental prognostic information by appropriately reclassifying patients with events to a higher risk category. Thus, these results suggest that an ASGES ≤15 not only may identify a subgroup of symptomatic patients with a low likelihood of oCAD, but also has clinical validity in identifying patients who are at low risk for requiring revascularization procedures in the short term. Larger studies with longer follow-up will be needed to quantify the risk of non-revascularization procedures in low-to moderate-risk patients with a high ASGES.
Due to their accepted sensitivity and specificity for diagnosing oCAD and ability to predict events, noninvasive diagnostic tests are often used early in the evaluation of patients with symptoms suggestive of oCAD. 2 The extent to which novel biomarkers can substitute for or add to noninvasive testing to diagnose oCAD is an area of active research. A number of previous studies have examined the relationship between peripheral blood gene expression and the presence of CAD; 23, 24 ). The ASGES is a clinically available diagnostic tool for patients presenting with symptoms suggesting oCAD. The ASGES is based on sex-specific age-dependent risk functions and the peripheral blood cell gene expression levels of 23 genes. 7 The use of age and sex in the ASGES algorithm is designed to capture the influences of age and sex on gene expression and likelihood of oCAD. 7 By design, the mean ASGES is higher in men than women (online Supplementary Figure 2) , as previously observed. 10 The gene expression component reflects changes in the composition and activation state of circulating peripheral blood cells in patients with oCAD. 7 Using a predefined cutoff of 15 to diagnose oCAD, 45% of PROMISE patients had a negative ASGES, which is similar to the COMPASS study. 10 In PROMISE, the ASGES was well calibrated; our findings extend the association of the ASGES with oCAD to a patient population that was at lower risk compared to patients in prior ASGES studies (PREDICT and COMPASS). However, the ASGES showed diminished diagnostic accuracy for oCAD compared to that observed previously (PROMISE AUC 0.625 ± 0.05 vs. AUC 0.70 ± 0.04 in PREDICT 8 and 0.79 ± 0.06 in COMPASS 10 ). This difference in performance may be driven by a number of factors, including 1) a lower prevalence of oCAD (10% in PROMISE CTA arm with available ASGES vs. 37% in PREDICT 8 and 15% in COMPASS 10 ); 2) clinical site CTA (in PROMISE) vs. core-lab CTA and/or invasive angiography (in PREDICT and COMPASS) defined oCAD; 25 and 3) age because there was no significant association between age and oCAD in the PROMISE CTA arm (P = .11) and age is used in the ASGES algorithm-a difference between this and previous studies used to develop and validate the ASGES. 8, 10 Nevertheless, our findings corroborate previous studies demonstrating that the ASGES is significantly associated with oCAD.
In clinical practice, identifying patients at lower risk for oCAD and revascularization can limit the need for further diagnostic testing which may involve radiation exposure and the use of contrast agents. In PROMISE, we used a composite primary endpoint that largely conformed to the definition used in our prior ASGES studies. However, in PROMISE, 12 stroke was not adjudicated outside of the peri-procedural window and thus was excluded from the primary endpoint definition. For the first time, we demonstrate that the ASGES is associated with revascularization procedures in symptomatic patients with suspected oCAD independent of Framingham risk factors. Consistent with previous studies, 8, 10 a low ASGES was associated with a low risk (1.6%, negative predictive value = 98%, Table II) of revascularization. From a clinical perspective, a low ASGES may provide confidence that the likelihood of oCAD and the need for revascularization in the short term are both very low. From a patient perspective, a low ASGES may provide reassurance that invasive cardiac catheterization and additional noninvasive diagnostic testing can be safely avoided. The limited overall prognostic performance of the ASGES relative to noninvasive test results (Table III) suggests that elevated scores (N15) have lower positive predictive values relative to other noninvasive tests. Therefore, this study shows that an ASGES b15 in patients with symptoms suggestive of oCAD identifies a group with a lower likelihood of oCAD and revascularization procedures in the near term.
A composite endpoint was chosen to maximize power to detect clinically relevant events in this patient population. The majority (98 of 143) of events were related to revascularization procedures, 99% of which occurred within 90 days of randomization. Analysis of individual endpoint components demonstrated that the independent association of ASGES was driven by revascularization procedures (Table II) . A lower ASGES is associated with a lower burden of CAD in PROMISE ( Figure 1 ) and in our prior studies. 8, 10, 22 Consistent with the expectation that CAD burden is a key factor in the decision to pursue revascularization, additional adjustment for oCAD partially attenuated the association between ASGES and revascularization. After accounting for major clinical risk factors through the FRS, no independent association between the ASGES and non-revascularization events (death, nonfatal MI, or UA; Table II ) was observed. However, we may be underpowered for non-revascularization endpoints based on the sample size and event rates in this study. The hazard ratio estimates for the continuous ASGES (Table II) and non-revascularization events were consistent in their direction of association with ASGES. Therefore, much larger studies with longer durations of follow-up may be required to detect an association of the ASGES and non-revascularization events in low-risk populations.
Our study has several strengths. The large sample size provides confidence around our findings related to the primary endpoint. The similarity between the patients in the biorepository and the overall PROMISE trial (online Supplementary Table II) and pragmatic trial design help ensure that our findings are applicable to clinical practice. The main limitations of the current work are its exclusion of patients with diabetes based on the observation that gene expression changes associated with oCAD in diabetic patients differ from those in nondiabetic patients, 7 the low number and power to study non-revascularization related events, and a focus on genes that were identified based on their association with oCAD rather than cardiovascular events.
Conclusion
In nondiabetic, stable patients presenting with symptoms suggestive of CAD, the ASGES is associated with oCAD, can improve risk stratification, and identifies individuals at low risk for cardiac revascularization procedures in the short term.
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